-
2024-519655-28-00
5
Premenopausal patients with high-risk HR-positive/HER2-negative breast
-
2025-520538-49-00
1
Moderate-Severe Hypoxic-Ischaemic Encephalopathy (HIE)
-
2025-520554-11-00
5
Cardiovascular Disease
-
2025-520565-51-00
5
small cell lung cancer
-
2025-522145-21-00
5
Metastatic hormone sensitive prostate cancer
-
2025-523400-72-00
4
Cystic fibrosis
-
2025-523544-12-00
5
Myelodysplastic neoplasms/syndromes (MDS)
-
2025-523793-16-00
4
Homeostatic iron regulator gene-related hereditary hemochromatosis
-
2025-522255-25-00
5
2026-05-18
Fallopian Tube Neoplasms
-
2023-508047-40-00
5
2026-04-30
Ovarian cancer
-
2025-520466-22-00
5
2026-04-29
Advanced Platinum-resistant Epithelial Ovarian Cancer
-
2025-522767-15-00
5
2026-01-27
Acute Myeloid Leukemia
-
2025-521514-26-00
5
2026-01-26
Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer W
-
2024-519901-36-00
5
2025-12-17
Patients with resected stage II-IIIA non-small cell lung cancer (NSCLC
-
2024-518007-22-00
5
2025-12-05
Prevention of monkeypox (mpox) infection
-
2025-521040-37-00
5
2025-11-26
HER2-positive early breast cancer
-
2024-518589-29-00
5
2025-08-21
Bronchiectasis
-
2024-512753-24-00
5
2025-08-05
Acute Myeloid Leukemia (AML)
-
2024-512733-32-00
5
2025-03-31
Acute Myeloid Leukemia (AML)
-
2024-513077-48-00
5
2024-12-19
O6-methylguanine methyltransferase (MGMT) unmethylated glioblastoma
-
2024-514135-17-00
5
2024-11-28
Immunoglobulin A Nephropathy
-
2023-503630-44-00
10
2024-11-20
Treatment of moderate-to-severe Atopic dermatitis
-
2023-504231-41-01
10
2024-10-02
Locally advanced or metastatic urothelial cancer
-
2023-504918-29-00
5
2024-08-22
Hormone receptor positive breast cancer